Treatment
Paradigm in
Fibrotic Disease
even if they are in the future.
About Remedy Cell
Remedy Cell is a clinical stage biopharmaceutical company focused on the discovery and development of cell-derived, cell-free, breakthrough secretome therapies for areas of unmet need in fibrotic disease.
Our proprietary technology has the potential to redefine fibrotic disease treatment, by enabling tissue regeneration and disease remission that will improve patients’ quality of life. Remedy Cell’s team consists of distinguished management, scientists, clinical experts, and international thought leaders who are working together to revolutionize the treatment of fibrotic diseases.
The company’s lead product, RC-0315, for the treatment of Idiopathic Pulmonary Fibrosis (IPF), is currently evaluated under a phase Ib clinical trial.
Remedy Cell is developing novel therapies for treatment of fibrotic disorders. Our science enables tissue repair and restores organ function. We have assembled a highly experienced team of experts to advance our pipeline of secretome-derived therapies with the goal of transforming the way fibrotic diseases are treated.
Remedy Cell is developing novel therapies for treatment of fibrotic disorders. Our science enables tissue repair and restores organ function. We have assembled a highly experienced team of experts to advance our pipeline of secretome-derived therapies with the goal of transforming the way fibrotic diseases are treated.
Drug Development
Our work is inspired by patients—they give our work purpose every day and remind us of why it is we do what we do.
Remedy Cell Ltd. was founded with a singular goal in mind—to leverage scientific advances in cell-derived therapies to develop novel treatments for patients suffering from fibrotic diseases.
The Activated Remedy cell Secretome (ARcS) is a novel proprietary platform that is derived from mesenchymal stem cells induced by a pre-defined controlled, cellular stress. This secretome holds the potential to treat a variety of fibrotic disorders. ARcS is a cell-based cell-free modality that leverages the advantages of cell therapy and overcomes its disadvantages.
Our Approach
We believe that the best therapeutic solution for patients does not lie in a single targeted approach, the mandate approach of drug development, but in a unique combination of proteins and other bioactive molecules contained in ARcS. ARcS support the scientific understanding that a multifactorial approach is required to successfully treat complex conditions driven by multiple pathological pathways such as Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic disorders.
Our Focus
We are focused exclusively on diseases known to be caused by the morphological changes and abnormal buildup of collagen and fibrotic tissue in various organs. Fibrosis can occur in many tissues within the body, such as the lungs, liver, kidney, brain, and heart, typically as a result of intensive inflammation or damage
Idiopathic Pulmonary Fibrosis – The Unmet Need
Idiopathic pulmonary fibrosis (IPF) is a complex chronic disease that affects the tissue environment of the air sacs, or alveoli, in the lungs. This condition develops when interstitial lung tissue becomes thick and stiff with an excessive buildup of collagen. Over time, these changes can cause permanent scarring in the lungs, called fibrosis, that making it progressively more difficult to breathe.
IPF affects approximately 3 million people worldwide. These patients have a median survival rate of two-three years, worse than many cancers. In the US alone, approximately 50,000 patients die from IPF per year.
There is currently no cure. Approved medications only slow disease progression and are associated with significant side effects and tolerability challenges. Thus, there is an urgent need for a therapeutic treatment option that effectively degrades fibrosis, regenerates tissue, and restores lung function. RC-O315, our lead product, with the potential to restore lung function, is currently ongoing a phase Ib clinical trial.
Preclinical Development
and Proof of Concept
Remedy Cell procured Precision Cut Lung Slices (PCLS) from 10 end-stage IPF patients. In the images to the right, the Activated Remedy Cell Secretome (RC-0315) was tested and shown to promote collagen fiber degradation in human fibrotic lung tissue.
RC-0315 demonstrates a 50% reduction in perialveolar collagen fiber width in human lung tissue explant. The decrease in collagen width would potentially improve blood oxygenation and restore lung function.
RC-0315 Mechanism of Action
Using proteomics, single cell RNA sequencing and bioinformatic integration we can suggest how RC-0315 functions as a multifactorial cell-free therapy simultaneously targeting different pathological pathways underlying IPF.
RC-0315 repairs lung tissue and restores pulmonary function by hitting multiple IPF-associated targets simultaneously. Remedy Cell has identified several Active Proteins in RC-0315 that hit relevant Lung-Tissue Molecular Targets. The effect of hitting these molecular targets results in Ligand-Receptor Interactions which we believe is the basis of the regenerative mechanism of RC-0315 in preclinical models including Precision Cut Lung Slices from end-stage IPF patients.
The Ligand-Receptor Interactions include well-known molecules as well as novel targets and collectively affect several lung resident cell types known to trigger and perpetuate pulmonary fibrosis.
RC-0315’s Novel Pathways
RC-0315 is a novel multifactorial, multi-proteinacious therapy that hits multiple IPF-associated targets simultaneously. This image details how it potentially works.
In 2024 the company plans on submitting an application to the Israel Ministry of Health to conduct a Phase I/IIa Study to determine the safety, tolerability, and preliminary efficacy of RC-0315, a mesenchymal stem cell derived secretome, for the treatment of Idiopathic Pulmonary Fibrosis.
